Please wait while the formulary information is being retrieved.
FOTIVDA (tivozanib HCl)
- Renal cell carcinoma
0.89 mg capsule
- 1 capsule (0.89 mg) by oral route once daily for 21 consecutive days, followed by 7 days off, of a 28-day cycle
1.34 mg capsule
- 1 capsule (1.34 mg) by oral route once daily for 21 consecutive days, followed by 7 days off, of a 28-day cycle
Default screening record
- 1 capsule (0.89 mg) by oral route once daily for 21 consecutive days, followed by 7 days off, of a 28-day cycle
- 1 capsule (1.34 mg) by oral route once daily for 21 consecutive days, followed by 7 days off, of a 28-day cycle
- None
Contraindicated
- None
Severe
Moderate
- None
- Invasive surgical procedure
- Lactation
- Nephrotic syndrome
- Posterior reversible encephalopathy syndrome
Contraindicated
- Acute myocardial infarction
- Cerebrovascular accident
- Chronic heart failure
- Hypertension
- Impaired wound healing
- Increased risk of bleeding
- Pregnancy
- Proteinuria
Severe
Moderate
- Hyperthyroidism
- Hypothyroidism
FOTIVDA (tivozanib HCl)
- Renal cell carcinoma
- Hypertension
- Hyponatremia
- Hypophosphatemia
- Anorexia
- Cough
- Diarrhea
- Elevated serum lipase
- Fatigue
- Hypothyroidism
- Nausea
- Stomatitis
- Voice change
More Frequent
Severe
Less Severe
- Arterial thrombosis
- Avascular necrosis of bone
- Heart failure
- Hemorrhage
- Hyperbilirubinemia
- Hyperthyroidism
- Increased alanine transaminase
- Increased aspartate transaminase
- Lymphopenia
- Thrombocytopenic disorder
- Venous thrombosis
- Delirium
- Hyperglycemia
- Increased hemoglobin
- Palmar-plantar erythrodysesthesia
- Prolonged activated partial thromboplastin time
- Proteinuria
- Skin rash
- Vomiting
- Weight loss
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Hypertensive crisis
- Impaired wound healing
- Myocardial ischemia
- Nephrotic syndrome
- Pneumonia
- Posterior reversible encephalopathy syndrome
Less Severe
- None
Contraindicated
None
Severe Precaution
Tivozanib
Safety and effectiveness not established in pediatric patients < 18 years. Potential risk of abnormal growth of bone and teeth.
- 1 Day – 18 Years
- Safety and effectiveness not established in pediatric patients < 18 years. Potential risk of abnormal growth of bone and teeth.
Management or Monitoring Precaution
None
Tivozanib
- Severity Level:
D
- Additional Notes: Based on drug pharmacology developmental toxicity is possible.
Contraindicated
Tivozanib
Avoid breastfeeding during treatment and for 1 month after last dose
General | Excretion Potential | Effect on Infant | Notes |
Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Avoid breastfeeding during treatment and for 1 month after last dose |
Precaution Exists
None
General | Excretion Potential | Effect on Infant | Notes |
None |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Renal cell carcinoma | |
C64 | Malignant neoplasm of kidney, except renal pelvis |
C64.1 | Malignant neoplasm of right kidney, except renal pelvis |
C64.2 | Malignant neoplasm of left kidney, except renal pelvis |
C64.9 | Malignant neoplasm of unspecified kidney, except renal pelvis |
0-9 | A-Z |
---|---|
C64 | Malignant neoplasm of kidney, except renal pelvis |
C64.1 | Malignant neoplasm of right kidney, except renal pelvis |
C64.2 | Malignant neoplasm of left kidney, except renal pelvis |
C64.9 | Malignant neoplasm of unspecified kidney, except renal pelvis |
Formulary Reference Tool